The 10th Annual Immuno-Oncology Summit was held in Boston during October 12-14, 2022. Creative Biolabs, as an exhibitor, successfully showcased at the 10th Annual Immuno-Oncology Summit at booth #9 and has attracted many attendees during its exhibition. Throughout the show, our team of professionals answered questions regarding drug development in the field of immuno-oncology for visiting guests and scientists.

Conference Programs of this summit covered the latest immuno-oncology developments:

  • Bispecific Antibodies for Cancer Immunotherapy
  • Advances in CAR-T Therapy
  • Preclinical and Translational Immuno-Oncology
  • Combination Immunotherapies for Cancer
  • Emerging Technologies for IO Targeting & Discovery
  • Emerging Cell-Based Immunotherapy
  • Overcoming Resistance to IO Therapy

In addition, the Combination Immunotherapies for Cancer Program brought together leading researchers and companies from the field of immuno-oncology to discuss strategies for early development, combination therapies with checkpoint inhibitors, as well as clinical strategies and clinical results.

Dr. Praveen Bommareddy, director of translational research in Replimune, gave a presentation about combination therapy of oncolytic virus and monoclonal antibody, entitled Clinical Biomarker Studies with an Enhanced Potency Oncolytic HSV Expressing an Anti-CTLA-4 Antibody as a Single Agent and Combined with Nivolumab in Patients with Advanced Solid Tumors Indicates Potent Immune Activation. He presented biomarker data in patients treated with RP2 alone or in combined use with nivolumab from an ongoing clinical trial. RP2 is a novel, enhanced-potency oncolytic HSV1 which expresses GM-CSF, an anti-CTLA-4 antibody-like molecule and the fusogenic gibbon ape leukemia virus membrane R-glycoprotein (GALV-GP R-). RP2 is currently under clinical development in a range of solid tumors alone or in combined use with nivolumab. Nevertheless, RP2 + nivolumab has resulted in deep and durable responses in patients who failed prior anti-PD1 therapy (SITC 2021).

The 10th Annual Immuno-Oncology Summit has drawn its curtain. Thank you for your enthusiastic attention to our booth, and we look forward to seeing you at the next Immuno-Oncology Summit.

Creative Biolabs is proud to exhibit and participate in industry conferences where our scientists showcase innovative drug discovery solutions. Whether diving into scientific research, biopharmaceutical discovery and development, or industrial manufacturing, we strongly encourage you to come and meet us at our upcoming conferences!